This federal Project Grant award of $392,409 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at Louisiana State University (LSU) on immune system evasion mechanisms used by the bacterial pathogen Staphylococcus aureus. The research aims to characterize how a specific S. aureus protein (SSL11) inhibits neutrophil function, understand the role of S. aureus superantigen-like proteins in colonization and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $390,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Colorado-Denver. The 5-year grant, which commenced on May 2, 2025, supports research to investigate the molecular basis of how the bacterial pathogen Staphylococcus aureus uses its unique serine protease-like (Spl) enzymes, particularly the Spl B variant, to manipulate host cell processes during infection....
This Project Grant award of $2,841,668.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research focused on understanding how the bacterial enzyme SagB in Staphylococcus aureus (S. aureus) modulates the host immune response and promotes infection. The key goals are to determine how SagB-modified peptidoglycan is recognized by immune cells, investigate the mechanism of SagB-dependent IL-1β...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $560,178 Project Grant to the University of Wisconsin - Madison. The goal of this 5-year grant, which runs from Jul 25, 2025 to Jun 30, 2030, is to understand the dynamics of the interaction between Staphylococcus aureus bacteriophages, the bacteria, and the mammalian host. Specifically, the research aims to elucidate the...
This federal Project Grant award, valued at $312,000.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support research conducted by the University of Texas Health Science Center at Houston (UTHealth) to develop a single-cell resolution understanding of pathogenesis and antibiotic tolerance in Staphylococcus aureus infections. The research aims to explore the...
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $677,325 federal Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) from the National Institute of Allergy and Infectious Diseases (NIAID). The 5-year grant, effective from August 1, 2025 to July 31, 2030, will support research to understand the mechanisms by which the bacterium Staphylococcus aureus utilizes exogenous fatty acids. The key objectives include: Elucidating...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to develop real-time detection methods for Staphylococcus aureus transmission in hospital settings. The $3,210,845 award to New York University aims to integrate whole-genome sequencing with weekly colonization sampling to analyze transmission dynamics and create predictive models that can...
This $3,021,822 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Georgetown University to investigate the role of branched-chain fatty acids in the physiology and virulence of Staphylococcus aureus, a leading cause of skin and soft tissue infections. The research aims to: 1) determine the pathway by which S. aureus salvages and synthesizes branched-chain fatty...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $267,310 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois in Chicago. The grant, awarded on August 27, 2024, supports research to evaluate the role of a lipoic acid transfer protein in Staphylococcus aureus metabolism and virulence. The project aims to determine how this lipoic acid transfer protein interfaces with other metabolic enzymes to control...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $231,700 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to Texas A&M University System Health Science Center to develop novel biologics for treating Staphylococcus aureus (S. aureus) infections, including antibiotic-resistant strains like methicillin-resistant S. aureus (MRSA). The research aims to characterize the binding and neutralization properties of engineered DARPin proteins against...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Program (CFDA 93.855), provides $480,522 to the University of South Florida to conduct research on the role and regulation of secreted proteases in Staphylococcus aureus infections.
The key objectives of this 5-year project are to: 1) Investigate the regulation of S. aureus secreted proteases, including the impact of a novel regulatory RNA and a unique two-component system on protease activity; and 2) Determine the specific roles of individual S. aureus secreted proteases in mediating survival and dissemination during septic infections, using advanced mass spectrometry techniques. This research aims to advance the scientific understanding of how S. aureus utilizes secreted proteases to modulate virulence factors and interact with the host during infection.